Landmark Research Study is Launched to Assess Impact of Personal Genet...(l of improving health outcomes in indivi...),Health

Date:10/9/2008

l of improving health outcomes in individuals across the population. Navigenics educates and empowers customers with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics' lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures. More information can be found at http://www.navigenics.com.

ABOUT AFFYMETRIX

Affymetrix GeneChip(R) microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Headquartered in Santa Clara, Calif., Affymetrix has about 1,100 employees worldwide and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore and maintains sales and distribution operations across Europe and Asia. More information about Affymetrix can be found at http://www.affymetrix.com.

ABOUT MICROSOFT

Microsoft is committed to improving health around the world through software innovation. Over the past 12 years Microsoft has steadily increased its investments in health, with a focus on addressing the challenges of health providers, health and social services organizations, payers, consumers and life sciences companies, worldwide. Microsoft closely collaborates with a broad ecosystem of partners and develops its own powerful health solutions, such
'/>"/>

SOURCE Scripps Translational Science Institute Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
2. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
3. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
4. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
5. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
6. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
7. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
8. Hospital Launches Landmark Emergency Medicine Project
9. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
10. Viatronix V3D-Colon Utilized in Another Landmark Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression